Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NovoSeven first approved therapy for acquired hemophilia
As a recombinant therapy, NovoSeven is not plasma-derived and poses no risk of human viral transmission through its use. NovoSeven was first introduced in 1999. The FDA approved
As a recombinant therapy, NovoSeven is not plasma-derived and poses no risk of human viral transmission through its use. NovoSeven was first introduced in 1999. The FDA approved
RX-0201 is a first-in-class signal inhibitor that directly blocks the production of Akt, a protein kinase that plays a key role in cancer progression. The clinical trial of
AeroLEF is a unique inhaled-delivery system in development for the treatment of moderate to severe pain, including cancer pain. AeroLEF is designed to permit patients to match dosage
Introgen provided an update of data from several studies of the drug, including its effect on tumors and also on which patient populations were most likely to benefit
Januvia, manufactured by Merck, belongs to a new breakthrough class of prescription medications called DPP-4 inhibitors that improves blood sugar control in patients with type 2 diabetes. Januvia
Schering-Plough will be responsible for the development, manufacturing and commercialization of over-the-counter (OTC) products with the lower dosage strength of 20 mg for heartburn-related indications. Santarus will continue
Genzyme will acquire AnorMed in a cash transaction valued at $13.50 per outstanding share, or approximately $580 million. Genzyme started the bidding war in August with a hostile
The study used Optimata's computerized technology known as the Virtual Cancer Patient Engine (VCP). The trial was aimed at testing the accuracy of the VCP in predicting the
The trial demonstrated safety and a statistically significant improvement in both motor function and brain metabolism at one year. It also confirmed the safety and tolerability of the
The trial assessed the safety and tolerability of Neurodex, a proprietary formulation of dextromethorphan and low dose quinidine. Patient assessments also demonstrated statistically significant improvements in sleep, present